Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Prices Stivarga With Crowded Colon Cancer Market In Mind

This article was originally published in The Pink Sheet Daily

Executive Summary

Ahead of schedule, FDA approves Stivarga (regorafenib), partnered with Onyx, for late-stage mCRC patients with few options left. Bayer prices drug at under $10,000 a month, on par with competing treatments.

You may also be interested in...



Market Snapshot: Zaltrap Changes Cost-Benefit Expectations For New Colon Cancer Drugs

Lilly’s Cyramza, Boehringer Ingelheim’s Vargatef and Taiho’s TAS-102 will join an increasingly crowded and price sensitive market in metastatic colorectal cancer in the coming years.

Bayer Oncology Keystone Nexavar Looks Good For Thyroid Indication

Adding indications for Nexavar is critical to Bayer HealthCare’s plan to become a major global player in cancer therapeutics, Bayer oncology leader says at ASCO.

Bayer/Onyx Stick To Advanced Cancer Setting With Stivarga’s GIST Indication

New indication for third-line gastrointestinal stromal tumors, an area of high unmet need, builds on candidate’s initial approval in advanced colon cancer.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074701

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel